BioSpace News Archive

Baylis Medical announced the first clinical use of the VersaCross® Large Access Solution in Canada, to perform a Left Atrial Appendage Closure procedure.

Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 clinical trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) plasma-derived therapy as a potential outpatient treatment for patients with coronavirus disease (COVID-19) that are at high risk of progression to severe disease.

The board of directors of Eli Lilly and Company (NYSE: LLY) announced today that Carolyn R. Bertozzi , Ph.D., has resigned from her role as an independent director of Lilly’s board.

Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia’s proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology.

Glucose monitoring is a necessary step toward managing diabetes. Diabetes is a clinical condition wherein the glucose level in the blood increases due to the inability of the pancreas to produce insulin.

The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach.

External pacemaker is also known as artificial pacemaker or transcutaneous pacemaker. It is an electrode-based medical device for the initial stabilization of hemodynamically significant bradycardias of all types.

Trastuzumab, sold under the brand Herceptin, is a monoclonal antibody used to treat patients suffering from HER2+ve breast cancer and gastric cancers.

The global market for cone beam computed tomography is likely to observe a strong competition among the leading players present in the market, states a new research study that has been presented by Transparency Market Research.

Elekta announced that is has established permanent legal entity in Indonesia’s capital, Jakarta in order to address the unmet need for high quality, modern cancer care.